Penumbra, Inc. (PEN)
320.84
+0.77
(+0.24%)
USD |
NYSE |
Jun 09, 12:55
Penumbra SG&A Expense (Quarterly) : 192.80M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Boston Scientific Corp. | 1.781B |
| Abbott Laboratories | 3.74B |
| Globus Medical, Inc. | 297.78M |
| Insulet Corp. | 317.20M |
| DexCom, Inc. | 349.70M |